Literature DB >> 23016864

Fibroblast growth factor receptor inhibitors.

Suneel B V S Kumar1, Lakshmi Narasu, Rambabu Gundla, Raveendra Dayam, Sarma J A R P.   

Abstract

Fibroblast growth factor receptors (FGFRs) play an important role in embryonic development, angiogenesis, wound healing, cell proliferation and differentiation. The fibroblast growth factor receptor (FGFR) isoforms have been under intense scrutiny for effective anticancer drug candidates. The fibroblast growth factor (FGF) and its receptor (FGFR) provide another pathway that seems critical to monitoring angiogenesis. Recent findings suggest that FGFR mediates signaling, regulates the PKM2 activity, and plays a crucial role in cancer metabolism. The current review also covers the recent findings on the role of FGFR1 in cancer metabolism. This paper reviews the progress, mechanism, and binding modes of recently known kinase inhibitors such as PD173074, SU series and other inhibitors still under clinical development. Some of the structural classes that will be highlighted in this review include Pyrido[2,3-d]pyrimidines, Indolin- 2-one, Pyrrolo[2,1-f][1,2,4]triazine, Pyrido[2,3-d]pyrimidin-7(8H)-one, and 1,6- Naphthyridin-2(1H)-ones.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23016864

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  12 in total

1.  Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.

Authors:  Hao Chen; Dan-Ping Shen; Zi-Zhen Zhang; Jia-Hua Liu; Yan-Ying Shen; Xing-Zhi Ni
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

2.  Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Authors:  Bei Cheng; Feng Gao; Erica Maissy; Peisheng Xu
Journal:  Acta Biomater       Date:  2018-12-05       Impact factor: 8.947

3.  [Conditioned medium from rat RSC96 cells promotes proliferation of oligodendrocyte progenitor cells in vitro].

Authors:  Qi Qi; An-You Zhu; He-Zuo Lv; Jian-Guo Hu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

4.  Overexpression of microRNA-1 promotes cardiomyocyte commitment from human cardiovascular progenitors via suppressing WNT and FGF signaling pathways.

Authors:  Tung-Ying Lu; Bo Lin; Yang Li; Arshi Arora; Lu Han; Cheng Cui; Claudia Coronnello; Yi Sheng; Panayiotis V Benos; Lei Yang
Journal:  J Mol Cell Cardiol       Date:  2013-08-09       Impact factor: 5.000

5.  Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Authors:  Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Head Neck       Date:  2016-02-05       Impact factor: 3.147

Review 6.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Authors:  Alessandra Pattarozzi; Elisa Carra; Roberto E Favoni; Roberto Würth; Daniela Marubbi; Rosa Angela Filiberti; Luciano Mutti; Tullio Florio; Federica Barbieri; Antonio Daga
Journal:  Stem Cell Res Ther       Date:  2017-05-25       Impact factor: 6.832

8.  MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.

Authors:  Lin Wang; Guanhua Song; Weiwei Tan; Mei Qi; Lili Zhang; Jonathan Chan; Jindan Yu; Jinxiang Han; Bo Han
Journal:  Oncotarget       Date:  2015-11-03

9.  Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.

Authors:  Terence G Hall; Yi Yu; Sudharshan Eathiraj; Yunxia Wang; Ronald E Savage; Jean-Marc Lapierre; Brian Schwartz; Giovanni Abbadessa
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

Review 10.  Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Authors:  Navid Sobhani; Anna Ianza; Alberto D'Angelo; Giandomenico Roviello; Fabiola Giudici; Marina Bortul; Fabrizio Zanconati; Cristina Bottin; Daniele Generali
Journal:  Cells       Date:  2018-07-15       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.